MDT

101.04

-0.62%↓

134.24

-1.9%↓

VEEV

217.58

+0.38%↑

HQY

82.79

-0.1%↓

NEOG

10.23

+1.49%↑

MDT

101.04

-0.62%↓

134.24

-1.9%↓

VEEV

217.58

+0.38%↑

HQY

82.79

-0.1%↓

NEOG

10.23

+1.49%↑

MDT

101.04

-0.62%↓

134.24

-1.9%↓

VEEV

217.58

+0.38%↑

HQY

82.79

-0.1%↓

NEOG

10.23

+1.49%↑

MDT

101.04

-0.62%↓

134.24

-1.9%↓

VEEV

217.58

+0.38%↑

HQY

82.79

-0.1%↓

NEOG

10.23

+1.49%↑

MDT

101.04

-0.62%↓

134.24

-1.9%↓

VEEV

217.58

+0.38%↑

HQY

82.79

-0.1%↓

NEOG

10.23

+1.49%↑

Home・Lista de Ações・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Abrir

1.26 -1.56

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.25

Máximo

1.3

Indicadores-chave
By Trading Economics
Rendimento	17M -26M
Funcionários	171
EBITDA	19M -23M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+132.56% upside

Dividendos
By Dow Jones
Próximos Ganhos	26 de fev. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-23M 79M
Abertura anterior	2.82
Fecho anterior	1.26

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

1.43 / 1.6 Suporte e Resistência

Pliant Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de jan. de 2026, 23:07 UTC

Ganhos

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 de jan. de 2026, 21:27 UTC

Ganhos

Texas Instruments 4Q Sales Rise, Profit Falls

27 de jan. de 2026, 23:55 UTC

Conversa de Mercado

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 de jan. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de jan. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 de jan. de 2026, 23:39 UTC

Conversa de Mercado

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 de jan. de 2026, 23:20 UTC

Ganhos

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 de jan. de 2026, 23:20 UTC

Ganhos

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 de jan. de 2026, 23:19 UTC

Ganhos

SK Innovation Posts Net Loss for Second Consecutive Year

27 de jan. de 2026, 23:19 UTC

Ganhos

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 de jan. de 2026, 23:18 UTC

Ganhos

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 de jan. de 2026, 23:18 UTC

Ganhos

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 de jan. de 2026, 23:11 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

27 de jan. de 2026, 23:11 UTC

Conversa de Mercado

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 de jan. de 2026, 23:07 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 de jan. de 2026, 22:17 UTC

Conversa de Mercado

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 de jan. de 2026, 22:06 UTC

Ganhos

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 de jan. de 2026, 21:51 UTC

Ganhos

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

27 de jan. de 2026, 21:43 UTC

Ganhos

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 de jan. de 2026, 21:41 UTC

Ganhos

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 de jan. de 2026, 21:38 UTC

Ganhos

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 de jan. de 2026, 21:32 UTC

Ganhos

Ampol: Modest Profit From F&I International in 2025

27 de jan. de 2026, 21:32 UTC

Ganhos

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 de jan. de 2026, 21:31 UTC

Ganhos

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 de jan. de 2026, 21:31 UTC

Ganhos

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 de jan. de 2026, 21:30 UTC

Ganhos

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 de jan. de 2026, 21:29 UTC

Ganhos

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 de jan. de 2026, 21:29 UTC

Ganhos

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 de jan. de 2026, 21:28 UTC

Ganhos

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Comparação entre Pares

Variação de preço

Pliant Therapeutics Inc Previsão

Preço-alvo

By TipRanks

132.56% parte superior

Previsão para 12 meses

Média 3 USD 132.56%

Máximo 4 USD

Mínimo 2 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

1.43 / 1.6Suporte e Resistência

Recent bearish events outweigh bullish events.

There is one bearish event.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.